INTRODUCTION {#s1}
============

Breast cancer is the most common cause of cancer mortality in women worldwide and in Asia. In Hong Kong, breast cancer accounts for 26.6% of all newly diagnosed cancers and 10.8% of all cancer deaths in females in 2014 \[[@R1]\]. It is predicted that, based on the present trend, there will be an exponential increase in breast cancer incidence in Hong Kong and other Asian countries, particularly China. The fact that inhabitants of Asian countries comprise 60% of the world\'s population has significant implications for public health planning in the region.

Hereditary breast and ovarian cancer syndrome (HBOC) is an inherited genetic disease, of which *BRCA1* and *BRCA2* gene mutations are a prevalent cause. About 10% of the breast cancer cases in Hong Kong are inherited \[[@R2]\], and *BRCA* mutation carriers have a higher risk of developing breast cancer (45-65%) or ovarian cancer (11-39%) by the age of 70 than those without a *BRCA* mutation. The prevalence and risk management for *BRCA* carriers were addressed by previous pre-clinical and clinical studies, resulting in recommendations for screening and risk-reduction intervention for *BRCA* carriers and their family members. Surveillance of women with *BRCA* mutations include annual MRI breast screening from the age of 25 years alternating with mammography screening (National Comprehensive Cancer Network guidelines). Preventive alternatives include taking endocrine risk reducing drugs (tamoxifen or raloxifene) for five years, or risk-reducing mastectomy and salpingo-oophorectomy. The latter have been shown to reduce the risks of breast and ovarian cancers by 90% and 85% respectively. Risk reducing prophylactic salpingo oophorectomy is also associated with reduced overall mortality rates in *BRCA* mutation carriers \[[@R3]--[@R5]\]. *BRCA* mutation carriers among triple negative breast cancer (TNBC) patients are more likely to benefit from platinum-based chemotherapeutic agents \[[@R6]\]. A new emerging class of poly ADP-ribose polymerase (PARP) inhibitors, such as olaparib and rucaparib, also showed promising responses for ovarian cancer patients with *BRCA* defects in delaying disease progression and extending time to subsequent chemotherapy in a metastatic setting \[[@R7]\]. Hence, determination of *BRCA* mutation status is becoming important for clinical management with the emerging data supporting its use in therapy decisions. Also, genetic counselling and clinical interventions can be offered to family members of the affected patients.

To date, thousands of different mutations have been identified in *BRCA1* and *BRCA2* genes. However, specific *BRCA1/2* recurrent mutations were more commonly seen in different ethnic groups due to founder effect. For example, three well-characterized founder mutations (*BRCA1* c.68_69delAG, c.5266dupC and *BRCA2* c.5946delT) account for majority of the mutations identified in Ashkenazi Jews, and was reported to have a frequency of about 2.6% in the population \[[@R8]--[@R10]\]. In China, increasing trends in breast cancer incidence and mortality were observed, with about 270,000 new cases in 2015 \[[@R11]\]. Several recurrent and founder mutations have been reported in Chinese populations from different geographic locations, examples are *BRCA1* c.981_982delAT and c.5470_5477del ATTGGGCA in Eastern China \[[@R12]\], *BRCA2* c.3109C\>T, c.7436_7805del370 and c.9097dupA in Hong Kong \[[@R13]\].

Although next-generation sequencing (NGS) platforms have become more popular for multi-gene panel testing \[[@R2]\], it is not readily accessible in most of the clinical laboratories due to limited resources, the need for bioinformaticians and data analysis of sequencing data. In the present study, we describe the development of a multiplexed, SNaPshot primer extension genotyping assay, which allows the rapid and cost-effective detection of targeted *BRCA1* and *BRCA2* mutations from breast and ovarian cancer patients in Chinese populations.

RESULTS {#s2}
=======

Patient and tumor characteristics {#s2_1}
---------------------------------

Based on the local data on *BRCA1/2* mutation spectrum and in combination with literature search, we selected 25 Chinese recurrent mutations at 13 *BRCA1* loci and 12 *BRCA2* loci (Table [1](#T1){ref-type="table"}) and developed the SNaPshot genotyping panel. The panel was used to screen *BRCA* mutation in local Chinese cohorts of 441 breast cancer and 155 ovarian cancer patients, and an overseas cohort of 79 breast cancer patients. To further demonstrate the feasibility of the SNaPshot genotyping panel in Chinese populations, we also collected information of *BRCA1/2* deleterious mutations from 84 overseas Chinese carriers.

###### List of frequently occurring *BRCA1/2* pathogenic mutations identified in Chinese breast/ovarian cancer patients

  Gene      Nucleotide change         Peptide change         Exon/intron
  --------- ------------------------- ---------------------- -------------
  *BRCA1*   c.470_471delCT            p.Ser157^\*^           8
            c.964delG                 p.Ala322Leufs^\*^19    11
            c.981_982delAT            p.Cys328^\*^           11
            c.2253_2254delGT          p.Met751Ilefs^\*^10    11
            c.3333delA                p.Glu1112Asnfs^\*^5    11
            c.3342_3345delAGAA        p.Glu1115^\*^          11
            c.3916_3917delTT          p.Leu1306Aspfs^\*^23   11
            c.4065_4068delTCAA        p.Asn1355Lysfs^\*^10   11
            c.4148C\>G                p.Ser1383^\*^          12
            c.4372C\>T                p.Arg1443^\*^          14
            c.5406+1_5406+3delGTA     p.Asp1778Glyfs^\*^27   IVS22
            c.5406+7A\>G              p.Asp1778Glyfs^\*^27   IVS22
            c.5470_5477del ATTGGGCA   p.Ile1824Aspfs^\*^3    24
  *BRCA2*   c.1832C\>A                p.Ser611^\*^           10
            c.2595delA                p.Glu866Lysfs^\*^8     11
            c.2808_2811delACAA        p.Ala938Profs^\*^21    11
            c.3109C\>T                p.Gln1037^\*^          11
            c.4965delC                p.Tyr1655^\*^          11
            c.5164_5165delAG          p.Ser1722Tyrfs^\*^4    11
            c.6591_6592delTG          p.Glu2198Asnfs^\*^4    11
            c.7007G\>T                p.Gly2313Alafs^\*^31   13
            c.7878G\>A                p.Trp2626^\*^          17
            c.8068_8069delGT          p.Val2690Phefs^\*^2    18
            c.9097dupA                p.Thr3033Asnfs^\*^11   23
            c.9294C\>G                p.Tyr3098^\*^          25

A total of 441 local Chinese breast cancer probands were recruited based on the high-risk selection criteria. The mean age of diagnosis was 47.11 years with the range from 18-87 years. Of these, 84 patients (19.05%) had developed bilateral breast cancer. Majority of the tumors (60.19%) were invasive ductal carcinoma (IDC, n=316) while 15.81% were ductal carcinoma *in situ* (DCIS, n=83). The histology of the tumors were shown in Table [2](#T2){ref-type="table"}, 332 (63.24%) were ER+, 44 (8.38%) were HER2+ and 59 (11.24%) were triple-negative.

###### Characteristics of 441 local Chinese breast cancer patients screened for *BRCA1/2* mutations

                                                                             441 tested probands   35 mutation carriers            
  -------------------------------------------------------------------------- --------------------- ---------------------- -------- ----------------
  **Mean age at diagnosis**                                                                        47.11 y                         42.36 y
  **Age range**                                                                                    18 -- 87 y                      22 -- 70 y
  **Age at breast cancer diagnosis**                                         **N**                 **Proportion**         **N**    **Proportion**
  Below 30                                                                   14                    3.17%                  3        8.57%
  30-39                                                                      104                   23.58%                 12       34.29%
  40-49                                                                      173                   39.23%                 13       37.14%
  50 or above                                                                150                   34.01%                 7        20.00%
  **Bilateral cases**                                                        84                    19.05%                 12       34.29%
  **Histology (Tumors ^a^)**                                                 **525**               **100%**               **47**   **100%**
  Ductal                                                                     316                   60.19%                 30       63.83%
  Lobular                                                                    18                    3.43%                  0        \-
  Medullary                                                                  7                     1.33%                  1        2.13%
  Ductal + Lobular                                                           2                     0.38%                  0        \-
  Ductal + Medullary                                                         1                     0.19%                  0        \-
  DCIS                                                                       83                    15.81%                 8        17.02%
  Others                                                                     27                    5.14%                  1        2.13%
  Unclassified                                                               71                    13.52%                 7        14.89%
  **Molecular subtypes (Tumors ^a^)**                                        **525**               **100%**               **47**   **100%**
  ER+                                                                        332                   63.24%                 25       53.19%
  ER-                                                                        11                    2.10%                  1        2.13%
  HER2+                                                                      44                    8.38%                  2        4.26%
  TNBC                                                                       59                    11.24%                 9        19.15%
  Unknown                                                                    79                    15.05%                 10       21.28%
  **Have both breast and ovarian cancer**                                                                                          
  Yes                                                                        10                    2.27%                  3        8.57%
  No                                                                         431                   97.73%                 32       91.43%
  **Family history of breast cancer (first- and second-degree relatives)**                                                         
  Yes                                                                        195                   44.22%                 21       60.00%
  No                                                                         246                   55.78%                 14       40.00%

^a^ Numbers include tumors from patients with bilateral cancers.

In the unselected cohort of 155 ovarian cancer probands (Table [3](#T3){ref-type="table"}), the mean age of diagnosis was 44.74 years with the range from 9-85 years, of whom 139 probands had ovarian cancers (94.56%), others had fallopian tube cancer (1.36%) and peritoneal cancer (2.04%). The vast majority (n=138, 89.03%) of patient population had epithelial ovarian tumors, in which the most common histological subtype was endometrioid carcinoma (n=50, 32.26%), followed by serous (n=36, 23.23%) and clear cell subtypes (n=24, 15.48%).

###### Characteristics of 155 local Chinese ovarian cancer patients screened for *BRCA1/2* mutations

                                                                                        155 tested probands   13 mutation carriers           
  ------------------------------------------------------------------------------------- --------------------- ---------------------- ------- ----------------
  **Mean age at diagnosis**                                                                                   44.74 y                        53.62 y
  **Age range**                                                                                               9 -- 85 y                      37 -- 85 y
  **Age at ovarian cancer diagnosis**                                                   **N**                 **Proportion**         **N**   **Proportion**
  Below 30                                                                              18                    11.61%                 0       \-
  30-39                                                                                 20                    12.90%                 1       7.69%
  40-49                                                                                 68                    43.87%                 4       30.77%
  50 or above                                                                           49                    31.61%                 8       61.54%
  **Histology**                                                                                                                              
  Epithelial                                                                            138                   89.03%                 13      100%
   Serous                                                                               36                    23.23%                 8       61.54%
   Clear cell                                                                           24                    15.48%                 1       7.69%
   Endometroid                                                                          50                    32.26%                 2       15.38%
   Mucinous                                                                             16                    10.32%                 0       \-
   Mixed                                                                                12                    7.74%                  2       15.38%
  Stromal                                                                               4                     2.58%                  0       \-
  Germ Cell                                                                             4                     2.58%                  0       \-
  Others                                                                                3                     1.94%                  0       \-
  Unclassified                                                                          6                     3.87%                  0       \-
  **Have both breast and ovarian cancer**                                                                                                    
  Yes                                                                                   9                     5.81%                  3       23.08%
  No                                                                                    146                   94.19%                 10      76.92%
  **Family history of breast or ovarian cancer (first- and second-degree relatives)**                                                        
  Yes                                                                                   38                    24.52%                 7       53.85%
  No                                                                                    117                   75.48%                 6       46.15%

*BRCA1/2* mutation status in local Chinese cohorts {#s2_2}
--------------------------------------------------

All the probands were subjected to *BRCA1/2* mutational screening with the SNaPshot genotyping panel. For those who tested negative, they were further assayed for *BRCA1*/*2* full-gene sequencing by amplicon-based NGS and large genomic rearrangements by multiplex ligation-dependent probe amplification (MLPA) (Figure [1](#F1){ref-type="fig"}). The prevalence of *BRCA1/2* pathogenic mutations among high-risk breast cancer patients was 7.94% (35/441). Of these, 4 *BRCA1* and 11 *BRCA2* mutation carriers were identified with the SNaPshot genotyping panel, showing a detection rate of 3.40% (15/441) among this cohort. Additionally, 5 *BRCA1* and 15 *BRCA2* mutations were identified by NGS/MLPA analysis. A great proportion of these *BRCA* carriers had family history of breast cancer (60%) compared with the non-carriers (40%) (p=0.013) (Table [2](#T2){ref-type="table"}). There was a statistical difference regarding young onset ≤40 years (p=0.018) but not those ≤45 years (p=0.068) between the carriers and non-carriers.

![Workflow of *BRCA1/2* mutation screening of 596 breast (BrCa) and ovarian cancer (OvCa) patients (local cohort) and 79 overseas Chinese breast cancer patients](oncotarget-09-7832-g001){#F1}

Among the ovarian cancer patients, *BRCA* mutations were identified in 8.39% (13/155) of the patients, including 9 *BRCA1* and 4 *BRCA2*. Of these, the SNaPshot genotyping panel identified 5 *BRCA1* and 1 *BRCA2* carriers, showing a detection rate of 3.87% (6/155) among the cohort. Thirteen mutation carriers had a mean age at diagnosis of 53.6 years (range 37-85) and all had epithelial carcinoma, in which higher proportions were serous tumors (Table [3](#T3){ref-type="table"}). Family history of breast/ovarian cancers is also a risk factor for detecting *BRCA* mutation between carriers (54.85%) and non-carriers (21.83%, p=0.017).

Overall, the prevalence of *BRCA1/2* mutations in this highly selected local Chinese cohort was 8.05% (48/596) and the yield of the SNaPshot genotyping panel was 3.52% (21/596), indicating that nearly half of the mutations were recurrent mutations. *BRCA1/2* mutations identified in this local Chinese HBOC cohort were listed in Table [4](#T4){ref-type="table"}. Interestingly, we identified 3 *BRCA1* mutations (c.4046_4047delinsA, c.212+3A\>G and c.5335delC) by NGS, which were novel to our Chinese *BRCA1/2* mutation spectrum and were only seen in ovarian cancer cases, but not in the breast cancer cases in the present cohort.

###### *BRCA1/2* mutations identified in Chinese patients with hereditary breast and ovarian cancer syndrome

  Gene      No of cases   Mutation (HGVS)         Amino acid change      Gender   Cancer type        Family history   SNaPshot panel   NGS/MLPA
  --------- ------------- ----------------------- ---------------------- -------- ------------------ ---------------- ---------------- ----------
  *BRCA1*                                                                                                                              
  1         1             c.212+3A\>G             p.Cys64^\*^            F        Ovarian            No               \-               NGS
  2         1             c.220C\>T               p.Gln74^\*^            F        Breast             No               \-               NGS
  3         3             c.964delG               p.Ala322Leufs^\*^19    F        Breast             Yes              Yes              \-
                                                                         F        Ovarian            Yes              Yes              \-
                                                                         F        Breast & Ovarian   Yes              Yes              \-
  4         2             c.2635G\>T              p.Glu879^\*^           F        Breast             No               \-               NGS
                                                                         F        Ovarian            Yes              \-               NGS
  5         1             c.3333delA              p.Glu1112Asnfs^\*^5    F        Ovarian            No               Yes              \-
  6         1             c.3342_3345delAGAA      p.Glu1115^\*^          F        Breast & Ovarian   No               Yes              \-
  7         1             c.3756_3759delGTCT      p.Ser1253Argfs^\*^10   F        Breast             No               \-               NGS
  8         1             c.4046_4047delinsA      p.Thr1349Lysfs^\*^17   F        Ovarian            Yes              \-               NGS
  9         3             c.4372C\>T              p.Gln1458^\*^          F        Breast & Ovarian   Yes              Yes              \-
                                                                         F        Breast             No               Yes              \-
                                                                         F        Breast             Yes              Yes              
  10        1             c.5193+1G\>A            p.Trp1718Ser fs^\*^2   F        Breast             Yes              \-               NGS
  11        1             c.5335delC              p.Gln1779Asnfs^\*^14   F        Ovarian            No               \-               NGS
  12        1             c.5406+1_5406+3delGTA   p.Asp1778Glyfs^\*^27   F        Ovarian            Yes              Yes              \-
  13        1             r.5194_5406del          p.His1732_Thr1802del   F        Breast & Ovarian   No               \-               MLPA
  *BRCA2*                                                                                                                              
  1         1             c.470_474delAGTCA       p.Lys157Serfs^\*^24    F        Breast             Yes              \-               NGS
  2         1             c.1244delA              p.His415Leufs^\*^15    F        Breast             Yes              \-               NGS
  3         1             c.1688G\>A              p.Trp563^\*^           F        Breast             Yes              \-               NGS
  4         1             c.1855C\>T              p.Gln619^\*^           F        Breast             Yes              \-               NGS
  5         1             c.2595delA              p.Glu866Lysfs^\*^8     F        Breast             Yes              Yes              \-
  6         2             c.2808_2811delACAA      p.Ala938Profs^\*^21    F        Breast             Yes              Yes              \-
                                                                         F        Breast             Yes              Yes              \-
  7         7             c.3109C\>T              p.Gln1037^\*^          F        Breast             No               Yes              \-
                                                                         F        Breast             No               Yes              \-
                                                                         M        Breast             Yes              Yes              \-
                                                                         F        Breast             Yes              Yes              \-
                                                                         F        Breast             Yes              Yes              \-
                                                                         F        Breast             Yes              Yes              \-
                                                                         F        Ovarian            No               Yes              \-
  8         1             c.3760G\>T              p.Glu1254^\*^          F        Breast             Yes              \-               NGS
  9         1             c.4440T\>G              p.Tyr1480^\*^          F        Breast             Yes              \-               NGS
  10        1             c.5722_5723delCT        p.Leu1908Argfs^\*^2    F        Breast             No               \-               NGS
  11        1             c.5851_5854delAGTT      p.Ser1951Trpfs^\*^11   F        Breast & Ovarian   Yes              \-               NGS
  12        1             c.5951_5952delAA        p.Lys1984Ilefs^\*^18   F        Breast             No               \-               NGS
  13        3             c.7133C\>G              p.Ser2378^\*^          F        Breast             Yes              \-               NGS
                                                                         F        Breast             No               \-               NGS
                                                                         F        Ovarian            No               \-               NGS
  14        1             c.7558C\>T              p.Arg2520^\*^          F        Breast             Yes              \-               NGS
  15        1             c.7999delA              p.Ser2776Alafs^\*^6    F        Breast & Ovarian   Yes              \-               NGS
  16        1             c.8331+2T\>C            r.7826_8331del506      F        Breast             Yes              \-               NGS
  17        1             c.8488-9T\>G            p.Trp2830Tyrfs^\*^36   F        Breast             Yes              \-               NGS
  18        2             c.9294C\>G              p.Tyr3098^\*^          F        Breast             Yes              Yes              \-
                                                                         F        Breast             No               Yes              \-
  19        1             c.9409dupA              p.Thr3137Asnfs^\*^13   F        Breast             No               \-               NGS
  20        1             c.10150C\>T             p.Arg3384^\*^          F        Ovarian            Yes              \-               NGS

All the *BRCA1/2* mutations detected by SNaPshot genotyping panel and NGS were confirmed by independent Sanger sequencing, and the results were consistent. In addition, no false negative from the SNaPshot genotyping panel was seen, implicating the accuracy and feasibility of the panel.

*BRCA1/2* mutation in overseas Chinese breast cancer patients {#s2_3}
-------------------------------------------------------------

In the second part of this study, we collected 79 blood samples from Chinese breast cancer probands residing in overseas countries including Australia, Taiwan and United States. We have identified 2 recurrent mutations (*BRCA2* c.3109C\>T and *BRCA2* c.4965delC) using the SNaPshot genotyping panel and a novel mutation *BRCA2* c.3165_3167delinsCC by NGS.

To further test the feasibility and reproducibility of the genotyping panel in Chinese emigrants, we additionally collected information of *BRCA1/2* mutation spectrum from overseas collaborating groups. We received data from 84 Chinese breast cancer patients who had known pathogenic *BRCA1/2* mutations, which included 63 different types of mutations (22 *BRCA1* and 41 *BRCA2*). Consistent with our local data, *BRCA2* mutation predominance was seen in overseas Chinese breast cancer patients. As shown in Table [5](#T5){ref-type="table"}, only 14 types of mutations were commonly seen in Hong Kong and overseas. Our SNaPshot genotyping panel covered 9 types of these mutations (3 *BRCA1* and 6 *BRCA2)* and should be able to pick up 17 out of the 84 carriers. The most predominant mutations in this overseas spectrum were *BRCA2* c.5164_5165delAG (n=4), c.7379_7382delACAA (n=4) and c.7878G\>A (n=4).

###### *BRCA1/2* mutations that seen in both Hong Kong and overseas spectrums

  Gene      Mutation (HGVS)      Amino acid change      Covered by SNaPshot genotyping panel
  --------- -------------------- ---------------------- --------------------------------------
  *BRCA1*   c.470_471delCT       p.Ser157^\*^           Yes
            c.3607C\>T           p.Arg1203^\*^          No
            c.4148C\>G           p.Ser1383^\*^          Yes
  *BRCA2*   c.755delA            p.Asp252Alafs^\*^25    No
            c.2808_2811delACAA   p.Ala938Profs^\*^21    Yes
            c.5164_5165delAG     p.Ser1722Tyrfs^\*^4    Yes
            c.5238dupT           p.Asn1747^\*^          No
            c.7007G\>T           p.Gly2313Alafs^\*^31   Yes
            c.7133C\>G           p.Ser2378^\*^          No
            c.7409dupT           p.Thr2471Hisfs^\*^4    No
            c.7558C\>T           p.Arg2520^\*^          No
            c.7878G\>A           p.Trp2626^\*^          Yes
            c.9097dupA           p.Thr3033Asnfs^\*^11   Yes
            c.9393delC           p.Lys3132Asnfs^\*^31   No

Note: *BRCA1* c.5470_5477del8 and *BRCA2* c.4965delC were not seen in the Hong Kong cohort, but were covered by the SNaPshot genotyping panel.

DISCUSSION {#s3}
==========

The genetic diagnosis of inherited breast cancer is clinically important in terms of disease management, and offering of genetic counseling and preventive strategies for family members who are at risk. The spectrum of *BRCA* mutation varies across countries and ethnicities, and the prevalence and dominance of *BRCA* mutation also varies among different populations \[[@R14], [@R15]\]. Even in Mainland China, there are more than 55 ethnic groups, in which Han, Manchu and Uyghur have the largest populations. Few studies have identified *BRCA* mutations in Chinese breast cancer patients, and the prevalence was lower than in the West \[[@R16], [@R17]\]. Identification of Chinese-specific *BRCA1/2* founder and recurrent mutations would be beneficial, not only to the Hong Kong patients of whom the majority are ethnically Chinese, but also to the enormous population in Mainland China and those emigrants in Western countries. The genetic testing panel was designed specifically for Chinese population to achieve better risk assessment and preventive measures \[[@R18]\].

It has been reported that *BRCA1* c.5589del8 and *BRCA2* c.3109C\>T are the most common recurrent mutations in Han Chinese \[[@R19]\], in which *BRCA2* c.3109C\>T has been confirmed to be a founder mutation in Southern Chinese \[[@R13]\]. It is of great importance to identify the prevalence of *BRCA1/2* or other high-penetrance genes in Chinese population, so that better risk assessment and clinical management can be offered to this subset of the population. In view of this, our pilot study was carried out to assess the prevalence of germline mutation in hereditary breast cancers in Hong Kong. Our previous results showed that less than 10% of the clinically high risk breast cancer patients harbor *BRCA1* and *BRCA2* mutations, and importantly, nearly half of the mutations were recurrent mutations \[[@R2], [@R13]\]. In consistent with our previous findings, the current mutational screening using the SNaPshot genotyping panel was able to pick up 3.52% (21/596) of *BRCA* carriers among the local cohorts, which covered 43.75% (21/48) of the identified mutations. Furthermore, *BRCA1* c.964delG (n=3), c.4372C\>T (n=3) and *BRCA2* c.3109C\>T (n=7) were the most common mutations identified by the SNaPshot panel in this study cohort (Table [4](#T4){ref-type="table"}). Besides, there were 27 mutation carriers identified by NGS full gene sequencing or MLPA. Of these, most of them were novel to our *BRCA* mutation spectrum, and *BRCA1* c.2635G\>T (n=2) and *BRCA2* c.7133C\>G (n=3) were newly identified recurrent mutations in Hong Kong cohort. It is expected that more recurrent *BRCA1/2* mutations will be identified as the cohort size increases, understanding the *BRCA* mutation spectrum is important to update and improve the coverage of the SNaPshot panel.

One of the limitations of the SNaPshot genotyping panel and amplicon-based NGS is that large genomic rearrangements in *BRCA1/2* genes could be not detected, which were reported to comprise up to 7% of all *BRCA* mutations in Asians \[[@R20]\]. Therefore, the incorporation of MLPA into *BRCA1/2* testing pipeline is necessary. In this study, one *BRCA1* large deletion (r.5194_5406 del) was identified from local breast cancer patient by this method (Table [5](#T5){ref-type="table"}) with a frequency of 2.08% (1/48) among all mutations. Notably, our previous study of a 1,236 high-risk Chinese HBOC patient cohort also showed 8 out of 120 identified mutations (6.67%) were large insertions/deletions \[[@R21]\].

By comparing the mutation spectra with overseas countries, *BRCA2* predominance is common among Chinese patients, which is concordant with the prevalence observed in the local cohort and other studies \[[@R19]\]. The *BRCA1* c.5470_5477delATTGGGCA and *BRCA2* c.7878G\>A were the most prevalent mutations among Chinese breast cancer patients that reside in US and other countries. The frequencies of *BRCA* mutations were 10.5% from a cohort of 409 Chinese breast cancer patients in Northern China, and *BRCA2* mutations were more common than *BRCA1* \[[@R22]\]. Large-scale population screening is warranted to unravel the frequencies and penetrance of *BRCA* mutations in Chinese population.

Identification and molecular diagnosis of HBOC families allow healthcare providers and professionals to decide on the clinical management guidelines and strategies. Substantial data from the West pointed to the importance of mutation screening and counselling \[[@R23]\], however, access to genetic services including genetic counselling in Mainland China is still inadequate. The cost of genetic testing and lack of coverage by local healthcare system are the main obstacles for mutation screening in Hong Kong and many parts of Asia \[[@R14]\]. Although next-generation sequencing is getting popular in the field of mutation screening, its high setup costs and the requirements of bioinformatics pipeline and sequencing data analysis are still challenging. Therefore, development of a genotyping panel for targeted recurrent mutation screening can offer a simple, rapid and affordable routine molecular diagnostic method that is feasible in most diagnostic laboratories. In our genetic testing workflow, initial screening using SNaPshot genotyping panel costs about USD 50 per sample with a turn-around time of 3 days, while the *BRCA1/2* full-gene sequencing with NGS cost about USD 1,500 per sample.

Data from this present study demonstrated around 10% of Chinese HBOC families had *BRCA* mutations which emphasizes the significant impact on breast cancer and ovarian cancer risk in the local population. Implementation of the SNaPshot genotyping panel in the mutation screening pipeline is feasible which helps to identify patients who are at risk, and may change the paradigm for treatment in this subset of patients who carry *BRCA* mutation.

MATERIALS AND METHODS {#s4}
=====================

Patients and DNA samples {#s4_1}
------------------------

441 high-risk breast cancer probands and 155 unselected ovarian cancer probands were recruited by Hong Kong Hereditary and High Risk Breast Cancer Programme (HRBCP) in Queen Mary Hospital and Tung Wah Hospital in Hong Kong. In addition, 79 overseas Chinese with breast and/or ovarian cancers were recruited from Australia, Taiwan and the United States. Written informed consent was obtained from all participating patients, and this study was approved by the Institutional Review Board (IRB) of The University of Hong Kong, and Hospital Authority Hong Kong West Cluster. Patient information including age, family history, and clinical reports were recorded (Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}). Genomic DNA was extracted from peripheral blood for *BRCA1/2* genetic testing using QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer\'s instructions.

Genetic testing selection criteria {#s4_2}
----------------------------------

High-risk breast cancer patients were recruited if any of the following criteria were met: (1) diagnosis of breast cancer at age ≤ 45 years; (2) bilateral breast cancer; (3) triple-negative or medullary type pathology; (4) male breast cancer; (5) at least one first- or second- degree relative with breast and/or ovarian cancer, regardless of age. In the unselected cohort of ovarian cancer, patients who had ovarian, fallopian tube or peritoneal cancer at any age were recruited.

Genetic testing workflow {#s4_3}
------------------------

Recruited breast and ovarian cancer probands were first tested for the 25 targeted *BRCA1/2* recurrent mutations using the SNaPshot genotyping panel (Table [1](#T1){ref-type="table"}). Those who tested negative were assayed for large genomic rearrangements by MLPA and amplicon-based NGS targeting all *BRCA1/2* exons \[[@R2]\]. All mutations identified by the SNaPshot genotyping panel and NGS were further verified by independent Sanger sequencing. The genetic testing workflow was illustrated in Figure [1](#F1){ref-type="fig"}.

Mutation screening by single base extension (SBE) assay (SNaPshot) {#s4_4}
------------------------------------------------------------------

Twenty-five *BRCA1/2* mutations, including founder and recurrent mutations reported in Chinese ethnic groups, were identified by our group \[[@R13]\] or from literature search \[[@R12], [@R22], [@R24], [@R25]\] (Table [1](#T1){ref-type="table"}). These mutations were reported in China, Hong Kong, Malaysia and Singapore Chinese populations, and were all small insertion/deletion or nonsense mutations. Primers designed for PCR amplification and SNaPshot genotyping assays (Applied Biosystems, Thermo Fisher Scientific, MA, USA) were listed in [Supplementary Tables 1 and 2](#SD1){ref-type="supplementary-material"}. The single base extension assay, SNaPshot, has been adopted for mutation screening. In brief, all 25 mutation loci were amplified by multiplex PCR. The mutations were examined by primers positioned immediately 5′ to the heterozygous bases. Single base extension reaction was performed in multiplex using the SNaPshot kit and modified primers with linkers of different repeating units of oligo TGAC. After purification, the SNaPshot products were run with 120 LIZ size standard in sequencing analyzer e.g. ABI Prism 3730. Data were processed by Genescan Analysis (Applied Biosystems). Relative intensity of the two alleles in each sample was calculated and confirmed the heterozygosity. The signal from the normal control DNA was used as reference.

Next-generation sequencing (NGS) {#s4_5}
--------------------------------

Samples tested negative from the SNaPshot genotyping panel were further assayed for *BRCA1/2* full-gene sequencing by NGS. The Fluidigm Access Array System (Fluidigm, San Francisco, USA) was used to generate separate pools of 74 PCR amplicons per sample for targeting all exons of the *BRCA* genes plus 10 bp from intron-exon boundaries as previously described \[[@R26]\]. 768 barcode combinations were used in rotation to minimize using the same combination in two consecutive runs. Paired-end sequencing of the amplicons (2 × 300bp) was performed on a MiSeq (Illumina, San Diego, USA) with reagent kit v3.

Sequences obtained from each sample were mapped to human genome reference GRCh37/hg19 using BWA-MEM version 0.7.7 with default parameters \[[@R27]\]. The minimum sequencing depth of coverage for ROI was 100x. Two variant callers were used: (1) Samtools version 0.1.9 \[[@R28]\], with mpileup command parameters -L 100000 -d 100000 to cater for amplicons with depth exceeding 250-fold and bcftools command parameter --m0.99 to use the new insertion-deletion (INDEL) calling model; (2) GATK HaplotypeCaller version 2.8-1 \[[@R29]\] according to the best practices as mentioned previously \[[@R2]\]. Variant calls were annotated by Ensembl Variant Effect Predictor version 75 \[[@R30]\]. The bioinformatic analysis was performed on a Cray XC30 supercomputer (Cray, Seattle, USA). Pathogenic mutations or ROI positions with depth of coverage below 100x were subject to Sanger sequencing and data analysis by Mutation Surveyor version 4.0.6 (Softgenetics Inc, USA).

*BRCA* mutation validation by DNA sequencing {#s4_6}
--------------------------------------------

All *BRCA* mutations identified from SNaPshot genotyping panel and NGS were further validated by Sanger sequencing. Sequencing results were compared with the reference DNA sequences using Variant Reporter software (Applied Biosystems) and then reviewed manually. Computational analysis for potential cryptic splice site mutations were performed using splice site prediction programs such as NNSPLICE and ESEF finder. All mutations were named according to the recommendations from Human Genome Variation Society (HGVS). Variant descriptions were checked by Mutalyzer Name Checker (<http://mutalyzer.nl>). DNA sequencing was supplemented by multiplex ligation dependent probe amplification (MLPA) to detect large deletions or rearrangements \[[@R21], [@R31]\].

SUPPLEMENTARY MATERIALS TABLES {#s5}
==============================
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